TESARO Announces Availability of ZEJULA® (niraparib) for Women With Recurrent Ovarian Cancer in Germany
15. Dezember 2017 04:00 ET
|
TESARO, Inc.
ZEJULA is the first PARP inhibitor approved in Europe for women with recurrent ovarian cancer, without the need for BRCA testing and regardless of biomarker statusZEJULA is the only PARP inhibitor to...
TESARO Announces Availability of VARUBI® (rolapitant) IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy in the United States
28. November 2017 08:00 ET
|
TESARO, Inc.
VARUBI injectable emulsion features ready-to-use, single-dose vialNo saline, reconstitution or mixing is required to utilize VARUBI IVNew formulation offers healthcare providers flexibility in their...
TESARO Announces Participation in Two Investor Conferences
22. November 2017 16:05 ET
|
TESARO, Inc.
WALTHAM, Mass., Nov. 22, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences....
TESARO Secures $500 Million Non-Dilutive Term Loan Financing
21. November 2017 08:00 ET
|
TESARO, Inc.
WALTHAM, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology focused biopharmaceutical company, announced today that it has entered into a definitive term loan agreement...
TESARO’s Mary Lynne Hedley and Lonnie Moulder Named EY National Entrepreneurs of the Year®
20. November 2017 08:00 ET
|
TESARO, Inc.
WALTHAM, Mass., Nov. 20, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc., an oncology-focused biopharmaceutical company, is proud to announce that co-founders Lonnie Moulder, CEO, and Mary Lynne Hedley,...
TESARO Announces European Commission Approval of ZEJULA® for Women With Recurrent Ovarian Cancer
20. November 2017 07:00 ET
|
TESARO, Inc.
ZEJULA is the first PARP inhibitor approved in Europe for women with recurrent ovarian cancer, regardless of BRCA mutation or biomarker statusApproval supported by robust data from a randomized,...
TESARO Announces Third-Quarter 2017 Operating Results
07. November 2017 16:05 ET
|
TESARO, Inc.
ZEJULA® was the most prescribed PARP inhibitor in U.S. with Q3 net sales of $39.4 millionPositive CHMP opinion issued for ZEJULA in E.U.; commercial launch anticipated to begin by year-endExpansion of...
TESARO Announces U.S. FDA Approval of VARUBI® IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy
25. Oktober 2017 19:15 ET
|
TESARO, Inc.
VARUBI injectable emulsion features a ready-to-use, single-dose vial for intravenous administrationAvailability of new formulation offers healthcare providers the flexibility to choose oral or IV...
TESARO to Announce Third-Quarter 2017 Financial Results on November 7, 2017
24. Oktober 2017 16:15 ET
|
TESARO, Inc.
WALTHAM, Mass., Oct. 24, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its third-quarter 2017 financial results on Tuesday, November 7, 2017, after the close of the U.S....
TESARO Announces Participation at Two Investor Conferences
23. Oktober 2017 16:15 ET
|
TESARO, Inc.
WALTHAM, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences....